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The development af anticancer drugs inhibiting angiogenesis has been an area of extensive research 
in the past decade. Angiogenesis is a requirement for tumor growth and metastasis and occurs 
through several signalling pathways. One key pathway that initiates prolileration and migration 01 
endothelial cells is signalling through the vascular endothelial growth lactor receptor-2 (VEGFR-2).' 
Therelore , small molecules Ihal block Ihis signalling palhway Ihrough inhibilion 01 VEGFR-2 tyrasine 
kinase aclivily could potentially inhibit angiogenesis and tumor growth. Recently works describing 
Ihienopyrimidines' and thienopyridine 1,3-diarylureas' as VEGFR-2 inhibitors have emerged in the 
literature. Here we present the synthesis 01 new 1-aryl-3-(4-(7-methylthieno[3,2-d]pyrimidin-4-
yloxy)phenyl)ureas 2 in high yields by reaction 01 4-[(7-methylthieno[3,2-d]pyridin-4-yl)oxy]aniline 1 
with arylisocyanates. The lormer was prepared by regioselective nucleophilic substitution 01 4-chloro-
7-melhyllhieno[3,2-d]pyrimidine wilh 4-aminophenol (Scheme). 
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Compounds 2 were evaluated as potential VEGFR-2 tyrosine kinase inhibitors using AuloDock Vina as 
molecular docking software. The receptor X-ray 3-D structure was oblained Iram lhe Prolein Dala 
Sank: VEGFR2 (PDS: 1YWN) and the estimated inhibition constanls (Ki) 01 the synlhesised 
compounds were obtained. ln order lo validale the molecular docking approach, the respective co-
crystallized ligand (LlF) and Sorafenib, a known drug that inhibit VEGFR-2, were docked lo the kinase 
domain. The difference belween the X-ray conlormation and lhe predicted docked conlormations 01 
both ligands as well as the difference between estimated Ki (Soralenib: 109 nM; LlF: 7 nM) and 
experimenlal Ki (Soralenib: 93 nM' , LlF : 2 nMs) were negligible, validaling lhe protein slruclures lar 
virtual screening wilh the synthesised compounds. 
The polenlial use 01 compounds 2 as lulure drugs was sludied by applying lhe Lipinski 's Rule 01 Five 
analysis and it was observed thal ali the compounds respecled Ihis rule. The estimaled values 01 Ki 
were 109 nM lar 2a, 354 nM lar 2b and 47 nM for 2c, showing thal lhe presence 01 lhe nilrile group 
makes this compound the most promising of this series. 
Moreover, the docking pose 01 lhe compounds wilh lhe besl docking score was analyzed in arder lo 
undersland lhe key interactions belween lhe compounds and the VEGFR-2 kinase domain slructure. 
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